mikeon88
管理員
 
UID 1
精華
0
積分 0
帖子 15453
閱讀權限 255
註冊 2007-1-14 用戶註冊天數 6305
用戶失蹤天數 0
114.136.33.39 |
|
|
AC Immune (NASDAQ:ACIU) -11.9% after-hours after an experimental Alzheimer’s disease drug from Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALY) failed to elicit "shock and awe" in presentation data at a medical meeting.
• BIIB also -11.9% post-market even as its BAN2401 drug slowed progression of the earliest stages of Alzheimer’s by 30%, but doctors and patient advocates said more information was needed from larger, longer studies.
• ACIU’s crenezumab currently is in Phase 3 studies for Alzheimer’s disease under a pact with Roche’s Genentech; ACIU’s shares had gained 77% since BIIB and Eisai reported initial data from their study on July 6.
• Source: Bloomberg First Word
|
|
|
